Correction to: Orphanet Journal of Rare Diseases (2021) 16:433
Following publication of the original article [1], we have been notified that we should add one more author to the authors’ group:
Jafar Kafaie 8
8 Department of Neurology, Saint Louis University School of Medicine, St. Louis, USA
The original article was updated.
References
Attarian, et al. A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcot–Marie–tooth type 1A. 2021;16:433. https://doi.org/10.1186/s13023-021-02040-8.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
The online version of the original article can be found at https://doi.org/10.1186/s13023-021-02040-8
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Attarian, S., Young, P., Brannagan, T.H. et al. Correction to: A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcot–Marie–Tooth type 1A. Orphanet J Rare Dis 19, 142 (2024). https://doi.org/10.1186/s13023-024-03110-3
Published:
DOI: https://doi.org/10.1186/s13023-024-03110-3